Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) had its price target dropped by research analysts at Piper Sandler to $3.00 in a report released on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler‘s price target points to a potential upside of 476.92% from the stock’s current price.
Several other brokerages have also recently weighed in on MIST. Cantor Fitzgerald assumed coverage on Milestone Pharmaceuticals in a research note on Thursday, August 20th. They issued an “overweight” rating and a $3.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, October 12th. HC Wainwright restated a “buy” rating on shares of Milestone Pharmaceuticals in a report on Thursday, September 3rd. Finally, Wall Street Zen raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Milestone Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $5.83.
Check Out Our Latest Report on MIST
Milestone Pharmaceuticals Price Performance
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Milestone Pharmaceuticals had a negative return on equity of 305.75% and a negative net margin of 1,860.76%. The company had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $1.00 million. As a group, analysts forecast that Milestone Pharmaceuticals will post -0.84 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Milestone Pharmaceuticals
Several large investors have recently made changes to their positions in MIST. RVW Wealth LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth approximately $994,000. Guardian Wealth Advisors LLC NC increased its position in Milestone Pharmaceuticals by 21.1% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock valued at $455,000 after buying an additional 59,200 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in Milestone Pharmaceuticals during the 1st quarter valued at approximately $397,000. TRU Independence Asset Management 2 LLC bought a new position in Milestone Pharmaceuticals during the 2nd quarter valued at approximately $201,000. Finally, Valeo Financial Advisors LLC raised its stake in Milestone Pharmaceuticals by 12.2% during the third quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock valued at $127,000 after buying an additional 16,000 shares during the last quarter. 86.18% of the stock is currently owned by hedge funds and other institutional investors.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.
Further Reading
- Five stocks we like better than Milestone Pharmaceuticals
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
